-
WNT5a/GSK3/β-Catenin Control of FAP Adipogenesis
2026-09-03
The reference study identifies the WNT5a/GSK3/β-catenin axis as a key regulator of adipogenic drift in skeletal-muscle fibro/adipogenic progenitors (FAPs). By combining pharmacological screening, mass cytometry, transcriptomic integration, network modeling, and mouse injury models, it links GSK3 inhibition and impaired WNT5a signaling to muscle fat accumulation and regenerative dysfunction.
-
Nystatin (Fungicidin): Ergosterol-First Assay Design
2026-09-03
Nystatin (Fungicidin) is more than a broad-spectrum polyene: it is a practical probe of ergosterol-dependent fungal vulnerability. This article presents an ergosterol-first framework for interpreting susceptibility, adhesion, biofilm, resistance, and formulation experiments.
-
Isochlorogenic Acid A Hydrogel for Wound Repair
2026-09-02
A 2026 study developed an amylopectin/carboxymethyl chitosan hydrogel containing Isochlorogenic acid A/Fe(III) co-assembled nanoparticles to address the compound’s poor aqueous compatibility while combining antibacterial and tissue-repair functions. The formulation showed strong activity against Escherichia coli and Staphylococcus aureus, supported cell migration, modulated inflammatory and vascularization-associated markers, and improved wound closure in an in vivo model.
-
Boc-D-FMK Workflows for Apoptosis Research
2026-09-02
Boc-D-FMK is a cell-permeable pan-caspase inhibitor for separating caspase-dependent cell death from inflammatory signaling and transcriptional effects. This workflow guide connects apoptosis and inflammation assays with a recent glioblastoma CYP2B6 study while emphasizing controls, dosing logic, and troubleshooting.
-
Z-VAD-FMK Workflow for Apoptosis Research
2026-09-01
Use Z-VAD-FMK to distinguish caspase-dependent apoptosis from broader drug-induced loss of viability, with a practical workflow for EGFR-inhibitor and immune-cell studies. This guide combines solvent handling, kinetic controls, orthogonal readouts, and troubleshooting for more defensible apoptosis inhibition experiments.
-
Naftifine HCl: Mechanism and Research Workflow
2026-09-01
Naftifine HCl is an allylamine antifungal agent that inhibits fungal squalene 2,3-epoxidase and disrupts ergosterol biosynthesis. The product dossier reports a 323.86 g/mol hydrochloride salt, high purity above 98%, defined organic-solvent solubility, and storage at −20°C.
-
Nigericin for pH and Mitochondrial Assays
2026-08-31
Nigericin is a potassium/hydrogen ion carrier for experimentally controlled intracellular pH modulation, mitochondrial membrane ion transport, and GSDMD-linked cell-death studies. This practical guide connects formulation, dose finding, orthogonal readouts, and antibiotic-metabolism research without overstating evidence across model systems.
-
NF 449 and Platelet P2 Receptor Inhibition
2026-08-31
The reference study established NF 449 as a useful antagonist for separating platelet P2X1 signaling from P2Y1 and P2Y12 responses. Its combination of receptor-level pharmacology, platelet aggregation assays, and mouse thrombosis models showed that selective P2X1 blockade can reduce thromboembolic activity while preserving bleeding time under the tested conditions.
-
YY1 Haploinsufficiency Rewires Corticogenesis
2026-08-30
This preprint uses patient-derived iPSCs, 2D and 3D neural models, single-cell multiomics, imaging, and gene-regulatory network reconstruction to show how YY1 haploinsufficiency disrupts corticogenesis in a cell-type-specific manner. Its central contribution is linking intrinsic defects in neural progenitors and neurons with a non-cell-autonomous inflammatory response in neighboring astrocytes, providing a mechanistic framework for Gabriele-de Vries syndrome.
-
PUFA-PL Biosynthesis in Rice Blast Pathogenicity
2026-08-29
A 2024 Mycology study identifies Fad2 and Acsl4 as lipid-biosynthetic enzymes that support Magnaporthe oryzae pathogenic development through PUFA-containing phospholipids and ferroptosis-associated lipid peroxidation. Its combined genetic, lipidomic, chemical-rescue, and protein-interaction evidence provides a mechanistic framework for studying fungal cell death as a potential rice blast control target.
-
Nystatin (Fungicidin) in Translational Assays
2026-08-28
Nystatin (Fungicidin) combines ergosterol-targeted membrane disruption with practical utility in Candida, mycoplasma, adhesion, resistance, and formulation studies. This guide shows how to build reproducible antifungal assays and how nanoparticle-uptake findings can inform—but not substitute for—future delivery experiments.
-
Oteseconazole (VT-1161) Assay Workflows
2026-08-28
Build more informative Candida susceptibility studies with Oteseconazole (VT-1161), a selective fungal CYP51 inhibitor suited to species panels, resistance profiling, and mechanism-linked validation. This guide combines practical dilution workflows with transporter-aware interpretation for translational antifungal research.
-
Hepatic sEH, Nrf2, and Osteoclastogenesis in Osteoporosis
2026-08-27
A recent Free Radical Biology and Medicine study identifies a liver–bone signaling axis in which hepatic soluble epoxide hydrolase alters circulating 14,15-EET and 14,15-DHET, suppressing Nrf2 activity and promoting osteoclastogenesis. By combining patient samples, an ovariectomy-induced mouse model, liver-specific knockdown, pharmacological inhibition, and transcriptomics, the study connects epoxyeicosatrienoic acids metabolism with redox imbalance and bone loss.
-
1-Phenyl-2-Pentanol and Liver Fibrosis
2026-08-27
The reference study identifies 1-phenyl-2-pentanol from Moringa oleifera leaves as an inhibitor of profibrotic activation in TGF-β1-stimulated LX-2 hepatic stellate cells. By combining fibrosis-marker analysis with proteomics and molecular docking, the work connects reduced extracellular-matrix signaling with possible modulation of the Wnt/β-catenin pathway while highlighting the need for in vivo validation.
-
JAK Inhibitors and Endothelial Cardiovascular Risk
2026-08-26
A 2025 ACR Open Rheumatology study compared six JAK inhibitors in cytokine-stimulated human endothelial cells, separating anti-inflammatory effects from changes linked to adhesion, coagulation, and cell death. The results show that reducing IL-6 does not necessarily normalize endothelial thrombo-inflammatory or viability pathways, highlighting the limits of treating JAK inhibitors as a uniform class.